Since 2015 when the first “positive” trials of intraarterial (IA) stroke technology (also commonly referred to as “endovascular therapy”) were announced, this new treatment has evolved tremendously and is currently the standard treatment of most patients with emergent large vessel occlusion (LVO). Devices such as stent retrievers and aspiration catheters allow higher recanalization rates than IA pharmacological thrombolysis and older, early thrombectomy devices could achieve. A variety of IA approaches is currently available, and selection of the optimal therapeutic intervention is based on clot location and size as well as the anatomy of the affected vessel. In this chapter, we review currently available treatment strategies for IA stroke and discuss relevant studies and their clinical significance and limitations.
Stroke is the second most common cause of mortality worldwide and is estimated to be the number 1 cause of death and disability in developing countries 1
. Intravenous (IV) thrombolysis with recombinant tissue plasminogen activator (rtPA) is an effective tool for the treatment of patients with acute ischemic stroke (AIS) and can be administered within the first...Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com